Author: admin

DelveInsight’s “Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Benign Prostatic Hyperplasia, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Benign Prostatic Hyperplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Benign Prostatic Hyperplasia Market Forecast

Some of the key facts of the Benign Prostatic Hyperplasia Market Report: 

• The Benign Prostatic Hyperplasia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In June 2022, Astellas Pharma Inc. and GO Therapeutics, Inc. announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas) and GO have entered into a strategic research collaboration and license agreement to develop novel Immuno-Oncology therapeutics
• In December 2021, Veru announced FDA Approval of ENTADFI, a new treatment for Benign Prostatic Hyperplasia.
• According to a study by Boyle et al. (n.d.), up to 60% of men over 60 may have hypertension, and 50% of men over 60 may have symptoms consistent with BPH. This suggests that even if their aetiologies are unrelated and they develop independently, at least one-eighth of all men over the age of 60 develop both symptomatic BPH and hypertension
• The most anticipated new treatments are Vibegron (Urovant Sciences) and DKF-313 (Dongkook Pharmaceutical), which are waiting for approval. In a phase II clinical trial, the novel medication AUS-131 from Ausio Pharmaceuticals was examined
• Obesity, heart and circulatory disease, type 2 diabetes, an increase in the geriatric population, and the anticipated approval of novel therapies like Vibegron (Urovant Sciences), DKF-313 (Dongkook Pharmaceutical), and AUS-131 (Ausio Pharmaceuticals) are the main factors driving the Benign Prostatic Hyperplasia market
• Key Benign Prostatic Hyperplasia Companies: Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, GlaxoSmithKline, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, JW Pharmaceutical, Bayer, Warner Chilcott, Materia Medica Holding, Ausio Pharma, Organon and Co, Nymox Corporation, and others
• Key Benign Prostatic Hyperplasia Therapies: DKF0313, Vibegron, AUS-131 (S-equo), GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Silodosin, Levitra (Vardenafil, BAY38-9456), WC3055, Afalaza, S-equol, MK0906, NX-1207, Tamsulosin, and others
• The Benign Prostatic Hyperplasia epidemiology based on age-specific cases analyzed that Benign Prostatic Hyperplasia is more common in older males as compared to those below 40 years
• The Benign Prostatic Hyperplasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Benign Prostatic Hyperplasia pipeline products will significantly revolutionize the Benign Prostatic Hyperplasia market dynamics.

Benign Prostatic Hyperplasia Overview

Men who have BPH, also known as benign prostatic hyperplasia, have enlarged prostates that are not malignant. Other names for benign prostatic hyperplasia are benign prostatic blockage and benign prostatic hypertrophy. The urethra is pinched and pressed against by the prostate as it grows in size. Bladder wall thickness increases.

Get a Free sample for the Benign Prostatic Hyperplasia Market Report:

https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-market

Benign Prostatic Hyperplasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Benign Prostatic Hyperplasia Epidemiology Segmentation:

The Benign Prostatic Hyperplasia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Benign Prostatic Hyperplasia
• Prevalent Cases of Benign Prostatic Hyperplasia by severity
• Gender-specific Prevalence of Benign Prostatic Hyperplasia
• Diagnosed Cases of Episodic and Chronic Benign Prostatic Hyperplasia

Download the report to understand which factors are driving Benign Prostatic Hyperplasia epidemiology trends @ Benign Prostatic Hyperplasia Epidemiology Forecast

Benign Prostatic Hyperplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Benign Prostatic Hyperplasia market or expected to get launched during the study period. The analysis covers Benign Prostatic Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Benign Prostatic Hyperplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Benign Prostatic Hyperplasia Therapies and Key Companies

• DKF0313: Dongkook Pharmaceutical
• Vibegron: Urovant Sciences
• AUS-131 (S-equo): Ausio Pharmaceuticals
• GI198745: GlaxoSmithKline
• DKF-313: Dongkook Pharma
• Silodosin: RECORDATI GROUP
• ASP4901: Astellas Pharma Inc
• Tadalafil: Eli Lilly and Company
• PRX302: Sophiris Bio Corp
• Silodosin: JW Pharmaceutical
• Levitra (Vardenafil, BAY38-9456): Bayer
• WC3055: Warner Chilcott
• Afalaza: Materia Medica Holding
• S-equol: Ausio Pharma
• MK0906: Organon and Co
• NX-1207: Nymox Corporation
• Tamsulosin: GlaxoSmithKline

Discover more about therapies set to grab major Benign Prostatic Hyperplasia market share @ Benign Prostatic Hyperplasia Treatment Market

Scope of the Benign Prostatic Hyperplasia Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Benign Prostatic Hyperplasia Companies: Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, GlaxoSmithKline, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, JW Pharmaceutical, Bayer, Warner Chilcott, Materia Medica Holding, Ausio Pharma, Organon and Co, Nymox Corporation, and others
• Key Benign Prostatic Hyperplasia Therapies: DKF0313, Vibegron, AUS-131 (S-equo), GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Silodosin, Levitra (Vardenafil, BAY38-9456), WC3055, Afalaza, S-equol, MK0906, NX-1207, Tamsulosin, and others
• Benign Prostatic Hyperplasia Therapeutic Assessment: Benign Prostatic Hyperplasia current marketed and Benign Prostatic Hyperplasia emerging therapies
• Benign Prostatic Hyperplasia Market Dynamics: Benign Prostatic Hyperplasia market drivers and Benign Prostatic Hyperplasia market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Benign Prostatic Hyperplasia Unmet Needs, KOL’s views, Analyst’s views, Benign Prostatic Hyperplasia Market Access and Reimbursement 

To know more about Benign Prostatic Hyperplasia companies working in the treatment market, visit @ Benign Prostatic Hyperplasia Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Benign Prostatic Hyperplasia Market Report Introduction

2. Executive Summary for Benign Prostatic Hyperplasia

3. SWOT analysis of Benign Prostatic Hyperplasia

4. Benign Prostatic Hyperplasia Patient Share (%) Overview at a Glance

5. Benign Prostatic Hyperplasia Market Overview at a Glance

6. Benign Prostatic Hyperplasia Disease Background and Overview

7. Benign Prostatic Hyperplasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Benign Prostatic Hyperplasia 

9. Benign Prostatic Hyperplasia Current Treatment and Medical Practices

10. Benign Prostatic Hyperplasia Unmet Needs

11. Benign Prostatic Hyperplasia Emerging Therapies

12. Benign Prostatic Hyperplasia Market Outlook

13. Country-Wise Benign Prostatic Hyperplasia Market Analysis (2019–2032)

14. Benign Prostatic Hyperplasia Market Access and Reimbursement of Therapies

15. Benign Prostatic Hyperplasia Market Drivers

16. Benign Prostatic Hyperplasia Market Barriers

17.  Benign Prostatic Hyperplasia Appendix

18. Benign Prostatic Hyperplasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Benign Prostatic Hyperplasia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | GSK, Dongkook Pharma, Urovant Sciences, Ausio Pharma, RECORDATI GROUP

DelveInsight’s “Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Autosomal Dominant Polycystic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Autosomal Dominant Polycystic Kidney Disease Market Forecast

Some of the key facts of the Autosomal Dominant Polycystic Kidney Disease Market Report: 

• The Autosomal Dominant Polycystic Kidney Disease market size was valued approximately USD 1,365 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The ADPKD pipeline shows activity with various compounds such as Tesevatinib/KD019, Bardoxolone methyl, GLPG2737, JNJ-0237/AT-20494, RGLS8429, and XRx-008. Some of these drugs are anticipated to be introduced during the forecast period of 2023-2032.
• In 2022, the collective diagnosed prevalent cases of ADPKD within the 7MM were approximately 368,479. It is projected that these diagnosed cases of ADPKD will experience an increase by the year 2032.
• In 2022, the United States reported roughly 143,708 diagnosed prevalent cases of ADPKD. In contrast, the combined diagnosed prevalent cases in the EU4 and the UK amounted to around 193,718 cases. These figures are anticipated to rise by the year 2032.
• In 2022, around 31,054 diagnosed prevalent cases of ADPKD were reported in Japan. Among these cases, approximately 26,396 were associated with mutations in the PKD1 gene, while 4,658 cases were linked to mutations in the PKD2 gene.
• Key Autosomal Dominant Polycystic Kidney Disease Companies: Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX Therapeutic, ReataPharmaceuticals, Kyowa Kirin, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, and others
• Key Autosomal Dominant Polycystic Kidney Disease Therapies: Bosutinib, Tolvaptan, Lixivaptan, Everolimus, OPC-41061, Rapamune, XRx-008, Bardoxolonemethyl, Tesevatinib/KD019, GLPG2737, JNJ-0237/AT-20494, RGLS8429, and others
• The ADPKD epidemiology based on mutation-specific cases analyzed that the mutation-specific distribution of the disease suggests a higher prevalence of ADPKD due to mutation in PKD1 gene than in PKD2 gene
• The Autosomal Dominant Polycystic Kidney Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Autosomal Dominant Polycystic Kidney Disease pipeline products will significantly revolutionize the Autosomal Dominant Polycystic Kidney Disease market dynamics.

Autosomal Dominant Polycystic Kidney Disease Overview

Autosomal Dominant Polycystic Kidney Disease is a genetic disorder characterized by the development of numerous fluid-filled cysts primarily within the kidneys. It is one of the most common inherited kidney disorders.

Get a Free sample for the Autosomal Dominant Polycystic Kidney Disease Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market

Autosomal Dominant Polycystic Kidney Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Autosomal Dominant Polycystic Kidney Disease Epidemiology Segmentation:

The Autosomal Dominant Polycystic Kidney Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Autosomal Dominant Polycystic Kidney Disease
• Prevalent Cases of Autosomal Dominant Polycystic Kidney Disease by severity
• Gender-specific Prevalence of Autosomal Dominant Polycystic Kidney Disease
• Diagnosed Cases of Episodic and Chronic Autosomal Dominant Polycystic Kidney Disease

Download the report to understand which factors are driving Autosomal Dominant Polycystic Kidney Disease epidemiology trends @ Autosomal Dominant Polycystic Kidney Disease Epidemiology Forecast

Autosomal Dominant Polycystic Kidney Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Autosomal Dominant Polycystic Kidney Disease market or expected to get launched during the study period. The analysis covers Autosomal Dominant Polycystic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Autosomal Dominant Polycystic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Autosomal Dominant Polycystic Kidney Disease Therapies and Key Companies

• Bosutinib: Pfizer
• Tolvaptan: Otsuka Pharma
• Lixivaptan: Palladio Biosciences
• Everolimus: Novartis Pharma
• OPC-41061: Otsuka Pharma
• Rapamune: Pfizer
• XRx-008: XORTX Therapeutic
• Bardoxolonemethyl: ReataPharmaceuticals/ Kyowa Kirin
• Tesevatinib/KD019: Sanofi
• GLPG2737: Galapagos NV
• JNJ-0237/AT-20494: Janssen Pharmaceuticals
• RGLS8429: RegulusTherapeutics

Discover more about therapies set to grab major Autosomal Dominant Polycystic Kidney Disease market share @ Autosomal Dominant Polycystic Kidney Disease Treatment Landscape

Autosomal Dominant Polycystic Kidney Disease Market Drivers

• Technological advances in diagnostic procedures due to an increasing focus on early diagnosis has reduced undiagnosed cases, thus persistent rising cases of diagnosed ADPKD offer opportunities to companies to launch new therapies in the market.
• Advances are being made in unravelling the genetic origins of ADPKD, in non-invasive monitoring and in predicting disease progression that will help in better disease management

Autosomal Dominant Polycystic Kidney Disease Market Opportunities

• Pre-symptomatic diagnosis and their application in the care and management of individuals at risk for ADPKD.
• Identification of biomarkers for early detection of ADPKD patients at high risk for progression will help better manage ADPKD patients and prevent their progression.

Scope of the Autosomal Dominant Polycystic Kidney Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Autosomal Dominant Polycystic Kidney Disease Companies: Pfizer, Otsuka Pharma, Palladio Biosciences, Novartis Pharma, XORTX Therapeutic, ReataPharmaceuticals, Kyowa Kirin, Sanofi, Galapagos NV, Janssen Pharmaceuticals, Regulus Therapeutics, and others
• Key Autosomal Dominant Polycystic Kidney Disease Therapies: Bosutinib, Tolvaptan, Lixivaptan, Everolimus, OPC-41061, Rapamune, XRx-008, Bardoxolonemethyl, Tesevatinib/KD019, GLPG2737, JNJ-0237/AT-20494, RGLS8429, and others
• Autosomal Dominant Polycystic Kidney Disease Therapeutic Assessment: Autosomal Dominant Polycystic Kidney Disease current marketed and Autosomal Dominant Polycystic Kidney Disease emerging therapies
• Autosomal Dominant Polycystic Kidney Disease Market Dynamics: Autosomal Dominant Polycystic Kidney Disease market drivers and Autosomal Dominant Polycystic Kidney Disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Autosomal Dominant Polycystic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Autosomal Dominant Polycystic Kidney Disease Market Access and Reimbursement 

To know more about Autosomal Dominant Polycystic Kidney Disease companies working in the treatment market, visit @ Autosomal Dominant Polycystic Kidney Disease Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Autosomal Dominant Polycystic Kidney Disease Market Report Introduction

2. Executive Summary for Autosomal Dominant Polycystic Kidney Disease

3. SWOT analysis of Autosomal Dominant Polycystic Kidney Disease

4. Autosomal Dominant Polycystic Kidney Disease Patient Share (%) Overview at a Glance

5. Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance

6. Autosomal Dominant Polycystic Kidney Disease Disease Background and Overview

7. Autosomal Dominant Polycystic Kidney Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Autosomal Dominant Polycystic Kidney Disease 

9. Autosomal Dominant Polycystic Kidney Disease Current Treatment and Medical Practices

10. Autosomal Dominant Polycystic Kidney Disease Unmet Needs

11. Autosomal Dominant Polycystic Kidney Disease Emerging Therapies

12. Autosomal Dominant Polycystic Kidney Disease Market Outlook

13. Country-Wise Autosomal Dominant Polycystic Kidney Disease Market Analysis (2019–2032)

14. Autosomal Dominant Polycystic Kidney Disease Market Access and Reimbursement of Therapies

15. Autosomal Dominant Polycystic Kidney Disease Market Drivers

16. Autosomal Dominant Polycystic Kidney Disease Market Barriers

17.  Autosomal Dominant Polycystic Kidney Disease Appendix

18. Autosomal Dominant Polycystic Kidney Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Autosomal Dominant Polycystic Kidney Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Pfizer, Otsuka Pharma, Novartis

DelveInsight’s “Acute Agitation and Aggression Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acute Agitation and Aggression, historical and forecasted epidemiology as well as the Acute Agitation and Aggression market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Acute Agitation and Aggression market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Acute Agitation and Aggression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Agitation and Aggression Market Insights

Acute Agitation and Aggression Overview

Acute agitation is defined as a state of unease or inner tension with or without excessive motor activity. The term aggression represents a behavioral expression of severe agitation with the potential to cause harm to self or others. The etiology of aggression or behavioral disturbance can be multifactorial. Leading causes of agitation are a new environment, drug intoxication or withdrawal, alcohol in the system, and general medical conditions.

Some of the key facts of the Acute Agitation and Aggression Market Report: 

• The Acute Agitation and Aggression market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to Siddiqui et al., Agitation and aggressive behaviors are reported in 33% of community-dwelling patients with dementia and 80% of institutionalized patients with dementia
• According to Siddiqui et al., Schizophrenia and bipolar disorders are chronic illnesses that commonly present with symptoms of acute agitation and aggression in the patients with Acute Agitation and Aggression
• Key Acute Agitation and Aggression Companies: Impel NeuroPharma Inc., and others
• Key Acute Agitation and Aggression Therapies: INP105, and others
• The Acute Agitation and Aggression epidemiology based on gender analyzed that gender is not significantly associated with aggression

Get a Free sample for the Acute Agitation and Aggression Market Report:

https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market

Key benefits of the Acute Agitation and Aggression Market report:

1. Acute Agitation and Aggression market report covers a descriptive overview and comprehensive insight of the Acute Agitation and Aggression Epidemiology and Acute Agitation and Aggression market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Acute Agitation and Aggression market report provides insights on the current and emerging therapies.
3. Acute Agitation and Aggression market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Acute Agitation and Aggression market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Acute Agitation and Aggression market.

Download the report to understand which factors are driving Acute Agitation and Aggression epidemiology trends @ Acute Agitation and Aggression Epidemiological Insights

Acute Agitation and Aggression Market  

The dynamics of the Acute Agitation and Aggression market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

Acute Agitation and Aggression Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Agitation and Aggression Epidemiology Segmentation:

The Acute Agitation and Aggression market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Acute Agitation and Aggression
• Prevalent Cases of Acute Agitation and Aggression by severity
• Gender-specific Prevalence of Acute Agitation and Aggression
• Diagnosed Cases of Episodic and Chronic Acute Agitation and Aggression

Acute Agitation and Aggression Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Agitation and Aggression market or expected to get launched during the study period. The analysis covers Acute Agitation and Aggression market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Agitation and Aggression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Acute Agitation and Aggression treatment, visit @ Acute Agitation and Aggression Medications

Acute Agitation and Aggression Therapies and Key Companies

• INP105: Impel NeuroPharma Inc.

Scope of the Acute Agitation and Aggression Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acute Agitation and Aggression Companies: Impel NeuroPharma Inc., and others
• Key Acute Agitation and Aggression Therapies: INP105, and others
• Acute Agitation and Aggression Therapeutic Assessment: Acute Agitation and Aggression current marketed and Acute Agitation and Aggression emerging therapies
• Acute Agitation and Aggression Market Dynamics: Acute Agitation and Aggression market drivers and Acute Agitation and Aggression market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Acute Agitation and Aggression Unmet Needs, KOL’s views, Analyst’s views, Acute Agitation and Aggression Market Access and Reimbursement 

Discover more about therapies set to grab major Acute Agitation and Aggression market share @ Acute Agitation and Aggression market forecast

Table of Contents 

1. Acute Agitation and Aggression Market Report Introduction

2. Executive Summary for Acute Agitation and Aggression

3. SWOT analysis of Acute Agitation and Aggression

4. Acute Agitation and Aggression Patient Share (%) Overview at a Glance

5. Acute Agitation and Aggression Market Overview at a Glance

6. Acute Agitation and Aggression Disease Background and Overview

7. Acute Agitation and Aggression Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Agitation and Aggression 

9. Acute Agitation and Aggression Current Treatment and Medical Practices

10. Acute Agitation and Aggression Unmet Needs

11. Acute Agitation and Aggression Emerging Therapies

12. Acute Agitation and Aggression Market Outlook

13. Country-Wise Acute Agitation and Aggression Market Analysis (2019–2032)

14. Acute Agitation and Aggression Market Access and Reimbursement of Therapies

15. Acute Agitation and Aggression Market Drivers

16. Acute Agitation and Aggression Market Barriers

17.  Acute Agitation and Aggression Appendix

18. Acute Agitation and Aggression Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Agitation and Aggression Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Impel NeuroPharma Inc

“Non-Hodgkin’s Lymphoma Pipeline”

“Non-Hodgkin’s Lymphoma Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Hodgkin’s Lymphoma Market.

The Non-Hodgkin’s Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report @ Non-Hodgkin’s Lymphoma pipeline analysis

Some of the key takeaways from the Non-Hodgkin’s Lymphoma Pipeline Report:

• Non-Hodgkin’s Lymphoma Companies across the globe are diligently working toward developing novel Non-Hodgkin’s Lymphoma treatment therapies with a considerable amount of success over the years. 
• Non-Hodgkin’s Lymphoma companies working in the treatment market are Bio-thera solutions, Mustang Bio, Roche, Scopus Biopharma, Rafael Pharmaceuticals, AbbVie, Janssen, TG Therapeutics, Tessa Therapeutics, Epizyme, MEI Pharma, Loxo Oncology, Debiopharm, Eli Lilly, Angiocrine Bioscience, Autous, Genetech, Allogene Therapeutics, CarsGen Therapeutics, ADC Therapeutics, Nektar Therapeutics, HUTCHMED, Nanjing Yoko Biomedical, Bristol Myers Squibb, AI therapeutics, and others are developing therapies for the Non-Hodgkin’s Lymphoma treatment.

• Emerging Non-Hodgkin’s Lymphoma therapies in the different phases of clinical trials are HMPL-523, Devimistat, LAM-002, Abemaciclib, AUTO4, CNCT19, CAR-CD19 T Cells, CC-99282, Ibrutinib, Venetoclax, LOXO-305, Obinutuzumab, NKTR-255, Naratuximab emtansine, Loncastuximab tesirine, GB226, TT11, CPI 818, BI-1206, AB-205, and others are expected to have a significant impact on the Non-Hodgkin’s Lymphoma market in the coming years.

• In a phase II clinical trial for patients with refractory/relapsed (R/R) large B cell lymphoma (LBCL), obinutuzumab was administered prior to Glofit monotherapy to reduce tumor load.
• The latest update showed a complete response (CR) rate of 38% and an overall response rate (ORR) of 59% with a median follow-up of 20.1 months.

Non-Hodgkin’s Lymphoma Overview

Non-Hodgkin’s lymphoma (NHL) is a type of cancer that affects the lymphatic system, which is part of the body’s immune system. NHL encompasses a diverse group of malignancies characterized by the abnormal growth of lymphocytes, a type of white blood cell. It can occur in various lymphatic tissues, including lymph nodes, bone marrow, and organs. NHL can present with different subtypes and varying degrees of aggressiveness. Common symptoms include swollen lymph nodes, fever, night sweats, fatigue, and unexplained weight loss. Treatment options depend on the subtype and stage of NHL and may include chemotherapy, radiation therapy, targeted therapy, immunotherapy, or stem cell transplantation.

Get a Free Sample PDF Report to know more about Non-Hodgkin’s Lymphoma Pipeline Therapeutic Assessment @ https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight

Emerging Non-Hodgkin’s Lymphoma Drugs Under Different Phases of Clinical Development Include:

• Venetoclax: AbbVie
• Ibrutinib: Janssen
• Naratuximab emtansine: Debiopharm
• NKTR-255: Nektar Therapeutics
• LOXO-305: Loxo Oncology
• LAM–002: AI Therapeutics
• CNCT19: Juventas Cell Therapy Ltd.
• GB226: Genor Biopharma
• BI-1206: BioInvent International
• CAR-CD19 T Cells: Carsgen therapeutics
• AUTO4: Autolus
• TT11: Tessa Therapeutics
• CC-99282: Celgene
• AB-205: Angiocrine Bioscience

Route of Administration

Non-Hodgkin’s Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Subcutaneous
• Intravenous
• Oral
• Injectable

Molecule Type

Non-Hodgkin’s Lymphoma Products have been categorized under various Molecule types, such as

• Small molecules
• Monoclonal antibodies

Non-Hodgkin’s Lymphoma Pipeline Therapeutics Assessment

• Non-Hodgkin’s Lymphoma Assessment by Product Type
• Non-Hodgkin’s Lymphoma By Stage and Product Type
• Non-Hodgkin’s Lymphoma Assessment by Route of Administration
• Non-Hodgkin’s Lymphoma By Stage and Route of Administration
• Non-Hodgkin’s Lymphoma Assessment by Molecule Type
• Non-Hodgkin’s Lymphoma by Stage and Molecule Type

DelveInsight’s Non-Hodgkin’s Lymphoma Pipeline Report covers around 150+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Non-Hodgkin’s Lymphoma product details are provided in the report. Download the Non-Hodgkin’s Lymphoma pipeline report to learn more about the emerging Non-Hodgkin’s Lymphoma therapies @ Non-Hodgkin’s Lymphoma pipeline analysis

Some of the key companies in the Non-Hodgkin’s Lymphoma Therapeutics Market include:

Key Non-Hodgkin’s Lymphoma companies developing therapies are Bio-thera solutions, Mustang Bio, Roche, Scopus Biopharma, Rafael Pharmaceuticals, AbbVie, Janssen, TG Therapeutics, Tessa Therapeutics, Epizyme, MEI Pharma, Loxo Oncology, Debiopharm, Eli Lilly, Angiocrine Bioscience, Autous, Genetech, Allogene Therapeutics, CarsGen Therapeutics, ADC Therapeutics, Nektar Therapeutics, HUTCHMED, Nanjing Yoko Biomedical, Bristol Myers Squibb, AI therapeutics, and others.

Non-Hodgkin’s Lymphoma Pipeline Analysis:

The Non-Hodgkin’s Lymphoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin’s Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin’s Lymphoma Treatment.
• Non-Hodgkin’s Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Hodgkin’s Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin’s Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Hodgkin’s Lymphoma drugs and therapies @ https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight

Non-Hodgkin’s Lymphoma Pipeline Market Drivers

Several drivers contribute to the growth of the Non-Hodgkin’s Lymphoma (NHL) pipeline market. Firstly, there is a continuous demand for improved treatment options for NHL patients, particularly for those with relapsed or refractory disease. This drives research and development efforts to discover novel therapies and advance existing treatments. Secondly, the increasing understanding of the molecular and genetic mechanisms underlying NHL has led to the development of targeted therapies that specifically address the unique characteristics of individual NHL subtypes. Thirdly, advancements in technology and diagnostic tools enable better patient stratification and identification of appropriate candidates for specific treatments. Lastly, favorable regulatory environments and expedited approval pathways for breakthrough therapies facilitate the entry of innovative treatments into the market.

Non-Hodgkin’s Lymphoma Pipeline Market Barriers

One of the barriers in the Non-Hodgkin’s lymphoma (NHL) pipeline market is the complex and heterogeneous nature of NHL itself. NHL comprises various subtypes with distinct molecular characteristics, making it challenging to develop targeted therapies that effectively address each subtype. Additionally, the limited understanding of the underlying mechanisms and genetic drivers of NHL subtypes hinders the identification and development of novel therapeutic targets. Regulatory hurdles and the high costs associated with clinical trials and drug development pose additional barriers, potentially limiting the number of experimental treatments progressing through the pipeline. Moreover, the competitive landscape and the availability of established treatment options may impact the willingness of pharmaceutical companies to invest in NHL research and development.

Request for Sample PDF Report for Non-Hodgkin’s Lymphoma Pipeline Assessment and clinical trials @ https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight

Scope of Non-Hodgkin’s Lymphoma Pipeline Drug Insight    

• Coverage: Global
• Key Non-Hodgkin’s Lymphoma Companies: Bio-thera solutions, Mustang Bio, Roche, Scopus Biopharma, Rafael Pharmaceuticals, AbbVie, Janssen, TG Therapeutics, Tessa Therapeutics, Epizyme, MEI Pharma, Loxo Oncology, Debiopharm, Eli Lilly, Angiocrine Bioscience, Autous, Genetech, Allogene Therapeutics, CarsGen Therapeutics, ADC Therapeutics, Nektar Therapeutics, HUTCHMED, Nanjing Yoko Biomedical, Bristol Myers Squibb, AI therapeutics, and others.
• Key Non-Hodgkin’s Lymphoma Therapies: HMPL-523, Devimistat, LAM-002, Abemaciclib, AUTO4, CNCT19, CAR-CD19 T Cells, CC-99282, Ibrutinib, Venetoclax, LOXO-305, Obinutuzumab, NKTR-255, Naratuximab emtansine, Loncastuximab tesirine, GB226, TT11, CPI 818, BI-1206, AB-205, and others.
• Non-Hodgkin’s Lymphoma Therapeutic Assessment: Non-Hodgkin’s Lymphoma current marketed and Non-Hodgkin’s Lymphoma emerging therapies
• Non-Hodgkin’s Lymphoma Market Dynamics: Non-Hodgkin’s Lymphoma market drivers and Non-Hodgkin’s Lymphoma market barriers

Table of Contents

1. Non-Hodgkin’s Lymphoma Report Introduction

2. Non-Hodgkin’s Lymphoma Executive Summary

3. Non-Hodgkin’s Lymphoma Overview

4. Non-Hodgkin’s Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Non-Hodgkin’s Lymphoma Pipeline Therapeutics

6. Non-Hodgkin’s Lymphoma Late Stage Products (Phase II/III)

7. Non-Hodgkin’s Lymphoma Mid Stage Products (Phase II)

8. Non-Hodgkin’s Lymphoma Early Stage Products (Phase I)

9. Non-Hodgkin’s Lymphoma Preclinical Stage Products

10. Non-Hodgkin’s Lymphoma Therapeutics Assessment

11. Non-Hodgkin’s Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Hodgkin’s Lymphoma Key Companies

14. Non-Hodgkin’s Lymphoma Key Products

15. Non-Hodgkin’s Lymphoma Unmet Needs

16 . Non-Hodgkin’s Lymphoma Market Drivers and Barriers

17. Non-Hodgkin’s Lymphoma Future Perspectives and Conclusion

18. Non-Hodgkin’s Lymphoma Analyst Views

19. Appendix

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Latest Developments in Non-Hodgkin’s Lymphoma Pipeline in 2024: Analysis of Clinical Trials, Therapies, Mechanisms of Action, and Route of Administration by DelveInsight

“Multiple Myeloma Market”

(New York, USA) DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Multiple Myeloma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Multiple Myeloma market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Multiple Myeloma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Multiple Myeloma market.

Request for a Free Sample Report @ Multiple Myeloma Market Forecast

Some facts of the Multiple Myeloma Market Report are:

• According to DelveInsight, Multiple Myeloma market is expected to grow at a decent CAGR by 2032.
• Leading Multiple Myeloma companies working in the market are GlaxoSmithKline, Bristol-Myers Squibb, Bluebird bio, Oncopeptides AB, Secura Bio, Amgen (Onyx therapeutics), Takeda Pharmaceutical, Millennium Pharmaceuticals, Sanofi, Karyopharm Therapeutic, Janssen Biotech, Bristol Myers Squibb, AbbVie, Takeda Pharmaceutical, Janssen Pharmaceutical, Bristol-Myers Squibb Company (Celgene), RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Aduro Biotech, ExCellThera, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners, Chipscreen Biosciences, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Cartesian Therapeutics, AstraZeneca, MorphoSys AG/I-Mab Biopharma and others.
• Key Multiple Myeloma Therapies expected to launch in the market are Venetoclax (ABT-199), Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M), REGN5458, Iberdomide (CC-220), Blenrep (Belantamab Mafodotin /GSK2857916), Abecma (Idecabtagene vicleucel/bb2121/ ide-cel), Pepaxto (melflufen/ melphalan flufenamide), Sarclisa (Isatuximab), Xpovio (Selinexor), Darzalex (Daratumumab) and others.
• Talquetamab received BTD from the US FDA in June 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38-antibody.
• KarMMa-3 Trial: A pivotal phase 3 trial of idecabtagene vicleucel (ide-cel; Abecma) for patients with relapsed/refractory multiple myeloma after 2 to 4 lines of therapy. The trial showed a median progression-free survival (PFS) of 13.3 months with ide-cel compared to 4.4 months for standard therapy.

Multiple Myeloma Overview

Multiple myeloma is a complex hematologic malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow. These malignant cells crowd out healthy blood-forming cells, leading to bone marrow dysfunction, anemia, and weakened immunity. Common symptoms include bone pain, fatigue, renal complications, and hypercalcemia. The disease’s intricate pathogenesis involves genetic alterations, immune dysregulation, and interactions with the bone microenvironment. Treatment approaches encompass chemotherapy, immunomodulatory drugs, proteasome inhibitors, stem cell transplantation, and emerging targeted therapies. Despite advancements, multiple myeloma remains incurable, requiring a multimodal approach for disease management and improved patient outcomes. Ongoing research seeks to elucidate its underlying mechanisms, refine therapeutic strategies, and develop novel agents to enhance patients’ quality of life and extend survival.

Learn more about Multiple Myeloma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/multiple-myeloma-market

Multiple Myeloma Market

The Multiple Myeloma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Multiple Myeloma market trends by analyzing the impact of current Multiple Myeloma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Multiple Myeloma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Multiple Myeloma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Multiple Myeloma market in 7MM is expected to witness a major change in the study period 2019-2032.

Multiple Myeloma Epidemiology

The Multiple Myeloma epidemiology section provides insights into the historical and current Multiple Myeloma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Multiple Myeloma market report also provides the diagnosed patient pool, trends, and assumptions. 

Explore more about Multiple Myeloma Epidemiology @ https://www.delveinsight.com/sample-request/multiple-myeloma-market

Multiple Myeloma Drugs Uptake

This section focuses on the uptake rate of the potential Multiple Myeloma drugs recently launched in the Multiple Myeloma market or expected to be launched in 2019-2032. The analysis covers the Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Multiple Myeloma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Multiple Myeloma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Multiple Myeloma Pipeline Development Activities

• Venetoclax (ABT-199): AbbVie and Roche
• JNJ-68284528 (LCAR-B38M/JNJ-4528): Janssen Biotech/Nanjing Legend Biotech
• Keytruda (Pembrolizumab): Merck Sharp & Dohme Corp.
• Cetrelimab (JNJ-63723283): Janssen Research & Development
• REGN5458: Regeneron Pharmaceuticals
• Felzartamab (MOR202): MorphoSys AG/I-Mab Biopharma
• Chidamide (Epidaza): Chipscreen Biosciences
• Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
• Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy: RAPA Therapeutics
• Encorafenib in combination with Binimetinib: Pfizer (Array Biopharma)
• CLR 131 (131-CLR1404): Cellectar Biosciences
• BL-8040: BioLineRx
• GVAX (GM-CSF) Vaccine: Celgene/Aduro Biotech
• ECT-001: ExCellThera
• TAK-079: Takeda
• GBR 1342 (ISB 1342): Glenmark (Ichnos Sciences SA)
• P-BCMA-101 CAR-T cells: Poseida Therapeutics
• Opdivo (Nivolumab): Bristol-Myers Squibb
• PBCAR269A: Precision BioSciences
• MP0250: Molecular Partners AG
• Teclistamab (JNJ-7957; JNJ-64007957): Janssen Pharmaceutical
• Descartes-11: Cartesian Therapeutics
• Imfinzi (Durvalumab): AstraZeneca
• Imbruvica (Ibrutinib): Abbvie (Pharmacyclics) and Johnson & Johnson

Request for a sample report to understand more about the Multiple Myeloma pipeline development activities @ https://www.delveinsight.com/sample-request/multiple-myeloma-market

Multiple Myeloma Therapeutics Assessment

Major key companies are working proactively in the Multiple Myeloma Therapeutics market to develop novel therapies which will drive the Multiple Myeloma treatment markets in the upcoming years are GlaxoSmithKline, Bristol-Myers Squibb, Bluebird bio, Oncopeptides AB, Secura Bio, Amgen (Onyx therapeutics), Takeda Pharmaceutical, Millennium Pharmaceuticals, Sanofi, Karyopharm Therapeutic, Janssen Biotech, Bristol Myers Squibb, AbbVie, Takeda Pharmaceutical, Janssen Pharmaceutical, Bristol-Myers Squibb Company (Celgene), RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Aduro Biotech, ExCellThera, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners, Chipscreen Biosciences, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Cartesian Therapeutics, AstraZeneca, MorphoSys AG/I-Mab Biopharma and others.

Learn more about the emerging Multiple Myeloma therapies & key companies @ https://www.delveinsight.com/sample-request/multiple-myeloma-market

Multiple Myeloma Report Key Insights

1. Multiple Myeloma Patient Population

2. Multiple Myeloma Market Size and Trends

3. Key Cross Competition in the Multiple Myeloma Market

4. Multiple Myeloma Market Dynamics (Key Drivers and Barriers)

5. Multiple Myeloma Market Opportunities

6. Multiple Myeloma Therapeutic Approaches

7. Multiple Myeloma Pipeline Analysis

8. Multiple Myeloma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Multiple Myeloma Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Multiple Myeloma Competitive Intelligence Analysis

4. Multiple Myeloma Market Overview at a Glance

5. Multiple Myeloma Disease Background and Overview

6. Multiple Myeloma Patient Journey

7. Multiple Myeloma Epidemiology and Patient Population

8. Multiple Myeloma Treatment Algorithm, Current Treatment, and Medical Practices

9. Multiple Myeloma Unmet Needs

10. Key Endpoints of Multiple Myeloma Treatment

11. Multiple Myeloma Marketed Products

12. Multiple Myeloma Emerging Therapies

13. Multiple Myeloma Seven Major Market Analysis

14. Attribute Analysis

15. Multiple Myeloma Market Outlook (7 major markets)

16. Multiple Myeloma Access and Reimbursement Overview

17. KOL Views on the Multiple Myeloma Market

18. Multiple Myeloma Market Drivers

19. Multiple Myeloma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Myeloma Market Trends & Forecasts 2032 | Drug Pipeline, FDA Approvals, and companies by DelveInsight | GSK, BMS, Bluebird bio, Oncopeptides AB, Secura Bio, Amgen, Takeda, Sanofi, Janssen

“Lumbar Degenerative Disc Disease Market”

“The Lumbar Degenerative Disc Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Lumbar Degenerative Disc Disease pipeline products will significantly revolutionize the Lumbar Degenerative Disc Disease market dynamics”

The Lumbar Degenerative Disc Disease market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Lumbar Degenerative Disc Disease market size from 2019 to 2032. The report also covers current Lumbar Degenerative Disc Disease treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Key Takeaways from the Lumbar Degenerative Disc Disease Market Report

• The increase in Lumbar Degenerative Disc Disease market size is a direct consequence of the increasing prevalent population of lumbar degenerative disc disease patients in the 7MM.
• The leading Lumbar Degenerative Disc Disease Companies working in the market include Spine BioPharma Inc, MCRA, Synthes USA HQ Inc, NuVasive, Globus Medical Inc, Spineology Inc, Ranier Technology Limited, DiscGenics Inc, Invibio Ltd, Yuhan Corporation, Orthofix Inc., Janssen Korea, Ltd, Eisai Inc, Angitia Biopharmaceuticals, DiscGenics Inc, Baxter Healthcare Corporation, Apatech Inc, Zimmer Biomet, and others
• Promising Lumbar Degenerative Disc Disease Pipeline Therapies in the various stages of development include YH14618, Intradiscal rhGDF-5, AGA111, Sodium Hyaluronate, ALLOB® cells with ceramic scaffold, AMG0103, Tylenol, MPC-06-ID, and others.
• On June 2023, Spine BioPharma Inc announced a study of phase 3 clinical trials for SB-01 for injection. The purpose of the study is to confirm the safety and effectiveness of SB-01. For Injection in adult patients with chronic low back pain and related disability due to Lumbar Degenerative Disc Disease. The primary effectiveness hypothesis is superiority of the investigational product relative to control in terms of the percentage of subjects improving in pain-related disability.
• On January 2023, DiscGenics Inc announced a study of phase 1 clinical trials for IDCT, Saline Solution and Sodium Hyaluronate. The purpose of this study is to compare the safety and preliminary efficacy of intradiscal injections of two doses of IDCT (Discogenic Cells + Sodium Hyaluronate vehicle) and two controls (saline, Sodium Hyaluronate vehicle) in subjects with chronic low back pain due to Degenerative Disc Disease (DDD) at one lumbar level from L3 to S1.

Discover more about therapies set to grab major Lumbar Degenerative Disc Disease Market Share @ Lumbar Degenerative Disc Disease Market Size

Lumbar Degenerative Disc Disease Overview

Degenerative disc disease (DDD) is a condition in which a damaged spinal disc causes pain; simply put, it is caused by “wear and tear” on a spinal disc. Lumbar degenerative disc disease in the lumbar spine, or lower back, refers to a syndrome in which age-related wear and tear on a spinal disc causes low back pain.

Lumbar Degenerative Disc Disease Epidemiology Segmentation in the 7MM

• Total Lumbar Degenerative Disc Disease Prevalent Cases
• Lumbar Degenerative Disc Disease Diagnosed Prevalent Cases
• Lumbar Degenerative Disc Disease Age-Specific Cases

Download the report to understand which factors are driving Lumbar Degenerative Disc Disease Epidemiology Trends @ Lumbar Degenerative Disc Disease Epidemiological Insights

Lumbar Degenerative Disc Disease Market Insights

The majority of the patients with lumbar Degenerative Disc Disease improve without surgical treatment. A course of at least6 weeks of physical therapy with an emphasis on core strengthening and stretching should be attempted. Nonsurgical interventions include cognitive therapy, lifestyle modification, and modification of the activity that may exacerbate the pain, NSAIDs, and epidural injections.

Lumbar Degenerative Disc Disease Market Landscape

The ultimate goal of management of lumbar Degenerative Disc Disease is to maintain the balance between synthesis and degradation of the ECM and subsequent disc hydration despite all of the degenerative factors involved, with the belief that maintenance or restoration of disc health accompanied by symptom reduction and prolonged function of the lumbar motion segment.

To know more about Lumbar Degenerative Disc Disease Treatment options, visit @ Lumbar Degenerative Disc Disease Drugs

Lumbar Degenerative Disc Disease Market Dynamics

The overall lumbar degenerative disc disease market dynamics are not robust but are anticipated to change in the coming years due to the expected launch of emerging therapies like MPC-06-ID, BRTX-100, and others.

Scope of the Lumbar Degenerative Disc Disease Market Report

• Coverage- 7MM
• Lumbar Degenerative Disc Disease Companies- Spine BioPharma Inc, MCRA, Synthes USA HQ Inc, NuVasive, Globus Medical Inc (NYSE: GMED), Spineology Inc, Ranier Technology Limited, DiscGenics Inc, Invibio Ltd, Yuhan Corporation, Orthofix Inc (NYSE:  OFIX)., Janssen Korea, Ltd, Eisai Inc (NYSE: ESALF), Angitia Biopharmaceuticals, DiscGenics Inc, Baxter Healthcare Corporation (NYSE: BAX), Apatech Inc, Zimmer Biomet (NYSE: ZBH), and others
• Lumbar Degenerative Disc Disease Pipeline Therapies- YH14618, Intradiscal rhGDF-5, AGA111, Sodium Hyaluronate, ALLOB® cells with ceramic scaffold, AMG0103, Tylenol, MPC-06-ID, and others
• Lumbar Degenerative Disc Disease Segmentation: Product Type, Molecule Type, Route of Administration

Learn more about the Lumbar Degenerative Disc Disease Pipeline Therapies in clinical trials @ Lumbar Degenerative Disc Disease Market Landscape

Table of Content

1. Key Insights
2. Executive Summary of Lumbar Degenerative Disc Disease (DDD)
3. Competitive Intelligence Analysis for Lumbar Degenerative Disc Disease (DDD)
4. Lumbar Degenerative Disc Disease (DDD): Market Overview at a Glance
5. Lumbar Degenerative Disc Disease (DDD): Disease Background and Overview
6. Patient Journey
7. Lumbar Degenerative Disc Disease (DDD) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Lumbar Degenerative Disc Disease Unmet Needs
10. Key Endpoints of Lumbar Degenerative Disc Disease (DDD) Treatment
11. Lumbar Degenerative Disc Disease Marketed Products
12. Lumbar Degenerative Disc Disease Emerging Therapies
13. Lumbar Degenerative Disc Disease (DDD): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Lumbar Degenerative Disc Disease Market Outlook
16. Access and Reimbursement Overview of Lumbar Degenerative Disc Disease (DDD)
17. KOL Views
18. Lumbar Degenerative Disc Disease Market Drivers
19. Lumbar Degenerative Disc Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Get in touch with our Business executive @ Lumbar Degenerative Disc Disease Market Drivers and Barriers

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lumbar Degenerative Disc Disease Market Size 2032: Drugs, Clinical Trials, FDA Approval and Companies by DelveInsight | Spine BioPharma, MCRA, Synthes USA HQ, NuVasive, Globus Medical Inc, Spineology